Citigroup Inc. lifted its holdings in Genomic Health, Inc. (NASDAQ:GHDX) by 20.5% in the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 11,466 shares of the medical research company’s stock after purchasing an additional 1,948 shares during the period. Citigroup Inc.’s holdings in Genomic Health were worth $373,000 at the end of the most recent reporting period.
Several other hedge funds have also made changes to their positions in GHDX. Dubuque Bank & Trust Co. grew its holdings in shares of Genomic Health by 8.4% in the second quarter. Dubuque Bank & Trust Co. now owns 4,897 shares of the medical research company’s stock valued at $159,000 after purchasing an additional 379 shares in the last quarter. Legal & General Group Plc grew its holdings in shares of Genomic Health by 48.7% in the first quarter. Legal & General Group Plc now owns 6,222 shares of the medical research company’s stock valued at $196,000 after purchasing an additional 2,038 shares in the last quarter. SG Americas Securities LLC grew its holdings in shares of Genomic Health by 37.8% in the second quarter. SG Americas Securities LLC now owns 6,122 shares of the medical research company’s stock valued at $199,000 after purchasing an additional 1,679 shares in the last quarter. Los Angeles Capital Management & Equity Research Inc. acquired a new position in shares of Genomic Health in the first quarter valued at approximately $218,000. Finally, Envestnet Asset Management Inc. grew its holdings in shares of Genomic Health by 13.6% in the first quarter. Envestnet Asset Management Inc. now owns 8,282 shares of the medical research company’s stock valued at $259,000 after purchasing an additional 993 shares in the last quarter. Hedge funds and other institutional investors own 88.90% of the company’s stock.
A number of research analysts recently weighed in on GHDX shares. Zacks Investment Research cut shares of Genomic Health from a “hold” rating to a “sell” rating in a report on Tuesday, August 1st. Piper Jaffray Companies restated a “hold” rating and issued a $31.00 price objective on shares of Genomic Health in a report on Thursday, August 3rd. BidaskClub cut shares of Genomic Health from a “hold” rating to a “sell” rating in a report on Friday, August 4th. Canaccord Genuity lowered their price target on shares of Genomic Health from $36.00 to $35.00 and set a “buy” rating for the company in a report on Tuesday, August 15th. Finally, Cowen and Company reiterated a “hold” rating and set a $34.00 price target on shares of Genomic Health in a report on Friday, September 1st. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and one has issued a buy rating to the company. The company has a consensus rating of “Hold” and an average price target of $31.83.
In other news, insider Phillip G. Febbo sold 3,174 shares of the firm’s stock in a transaction that occurred on Wednesday, July 19th. The shares were sold at an average price of $33.57, for a total transaction of $106,551.18. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider James J. Vaughn sold 8,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 8th. The stock was sold at an average price of $30.59, for a total transaction of $244,720.00. The disclosure for this sale can be found here. Insiders have sold 36,174 shares of company stock valued at $1,129,171 in the last three months. Corporate insiders own 46.20% of the company’s stock.
Genomic Health, Inc. (NASDAQ:GHDX) opened at 32.99 on Tuesday. The firm’s 50-day moving average is $31.67 and its 200 day moving average is $31.66. Genomic Health, Inc. has a 12-month low of $26.37 and a 12-month high of $33.97. The firm’s market cap is $1.14 billion.
Genomic Health (NASDAQ:GHDX) last posted its quarterly earnings data on Tuesday, August 1st. The medical research company reported ($0.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.02). The firm had revenue of $85.50 million for the quarter, compared to analysts’ expectations of $86.08 million. Genomic Health had a negative net margin of 1.50% and a negative return on equity of 4.33%. The company’s revenue for the quarter was up 4.3% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.18) EPS. Equities research analysts predict that Genomic Health, Inc. will post ($0.03) EPS for the current year.
Genomic Health Company Profile
Genomic Health, Inc is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test.
Receive News & Ratings for Genomic Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.